Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Is an Acquisition of Acceleron a Smart Move for Merck?
Is an Acquisition of Acceleron a Smart Move for Merck?
Is an Acquisition of Acceleron a Smart Move for Merck?
Submitted by
admin
on October 8, 2021 - 10:35am
Source:
Motley Fool
News Tags:
Merck
M&A
Acceleron
PAH
Keytruda
Headline:
Is an Acquisition of Acceleron a Smart Move for Merck?
snippet:
Merck will get promising pulmonary arterial hypertension drug sotatercept with its acquisition of Acceleron.
Acceleron already has one drug on the market that's licensed to Bristol Myers Squibb.
An acquisitions strategy helps Merck reduce its dependence on blockbuster cancer drug Keytruda.
Do Not Allow Advertisers to Use My Personal information
